Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Recruiting · NCT07127822 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer | Gastric / Gastroesophageal Junction Adenocarcinoma; MSI-H Cancer | Recruiting | Phase 2 | 2026-08-05 | NCT07127822 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University | 124 |
| Peking University Cancer Hospital & Institute | 189 |
| Qilu Pharmaceutical Group Co., Ltd | 2 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of GI Oncology, Peking University Cancer Hospital | Beijing | China | 1 |
| Harbin Medical University Cancer Hospital | Harbin | China | 51 |
| Jiangsu Provincial People's Hospital | Nanjing | China | 21 |
| Shanxi Cancer Hospital | Taiyuan | China | 25 |
| The Affiliated Hospital of Qingdao University | Qingdao | China | 48 |
| The First Affiliated Hospital of Xi'an Jiao Tong University） | Xi'an | China | 1 |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | China | 103 |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang | China | 33 |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin | China | 23 |
| West China Hospital, Sichuan University | Chengdu | China | 41 |